CLOs on the Move

Actavis

www.actavis.com

 
Actavis is a unique global specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland. Actavis markets a broad portfolio of branded pharmaceuticals and is focused on developing new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis is also the world`s third-largest generics prescription drug manufacturer, marketing generic, branded generic, and Over-the-Counter (OTC) products in more than 60 countries. Actavis Global Operations has more than 35 ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.actavis.com
  • 400 Interpace Pkwy
    Parsippany, NY USA 07054
  • Phone: 862.261.7000

Executives

Name Title Contact Details
Robert Bailey
General Counsel Profile

Similar Companies

Industrial Pharmaceutical Resources

Industrial Pharmaceutical Resources is a Bartlett, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZestDentalSolutions

ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.

far east summit

far east summit is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

Capital i

BeClinic | Best WordPress theme for clinics and medicine